The Dose of Growth Factors Influences the Synergistic Effect of Vascular Endothelial Growth Factor on Bone Morphogenetic Protein 4–Induced Ectopic Bone Formation

Guangheng Li, M.D., Ph.D.,1 Karin Corsi-Payne, Ph.D.,1 Bo Zheng, M.D.,1 Arvydas Usas, M.D.,1 Hairong Peng, M.D., Ph.D.,2 and Johnny Huard, Ph.D.1

Although vascular endothelial growth factor (VEGF) has been shown to act synergistically with bone morphogenetic protein (BMP)2 and BMP4 to promote ectopic endochondral bone formation via cell-based BMP gene therapy, the optimal ratio of VEGF to either of the BMPs required to obtain this beneficial effect remains unclear. In the current study, two cell types (C2C12, NIH-3T3) were retrovirally transduced to express BMP4 only or both BMP4 and VEGF. The resulting groups of cells were tested for their cellular proliferation, in vitro mineralization capacity, survival potential, and ability to undergo ectopic bone formation when implanted into a gluteofemoral muscle pocket created in severe combined immunodeficient mice. Results showed that VEGF inhibited the in vitro calcification of C2C12 and NIH-3T3 cells transduced to express BMP4. In vivo, C2C12 and NIH-3T3 cells expressing BMP4 and VEGF displayed significantly less bone formation than the same cells expressing only BMP4. In vivo, our results indicated that, when the ratio of VEGF to BMP4 is high, a detrimental effect on ectopic bone formation is observed; however, when the ratio is kept low and constant over time, the detrimental effect that VEGF has on ectopic bone formation is lost. Our studies revealed that VEGF’s synergistic role in BMP4 induced ectopic bone formation is dose and cell-type dependent, which is an important consideration for cell-based gene therapy and tissue engineering for bone healing.

Introduction

Endochondral bone formation begins as a mesenchymal condensation, which then undergoes cartilage formation and cartilage resorption, coupled with blood vessel invasion and ultimately bone formation. Vascular endothelial growth factor (VEGF) is involved in all of the above steps, which are known to occur during embryonic development of long bones and the healing of bone fractures.1–4 The essential role of VEGF for the survival of chondrocytes during embryogenesis has been shown using a VEGF knockout mouse model.5 The VEGF knockout mice exhibited massive chondrocyte death at the center of the epiphysis at embryonic day 16.5 (E16.5), suggesting that VEGF may have a direct role in chondrocyte survival.5 VEGF has also been shown to play an important role in regulating cartilage resorption and blood vessel invasion, because it is believed to be actively responsible for hypertrophic cartilage neovascularization through a paracrine release by hypertrophic chondrocytes, with invading endothelial cells as the target.5–8 Alternatively, the blocking of VEGF via the systemic administration of a soluble receptor chimeric protein (Flt-(1-3)-IgG) led to a suppression of blood vessel invasion into the growth plate, concomitant with impaired trabecular bone formation and expansion of the hypertrophic chondrocyte zone.9 Capillary invasion and restoration of the bone growth plate architecture followed removal of the anti-VEGF treatment. Taken together, these findings indicate that VEGF is an essential coordinator of chondrocyte death, chondroclast function, extracellular matrix remodeling, and angiogenesis in the growth plate.9

VEGF also plays an important role in osteoblast biology. It has been shown to induce migration, parathyroid hormone–dependent accumulation and an increase in alkaline phosphatase (ALP) in osteoblasts. It is also thought to be an important regulator of osteoblastic differentiation.10 Osteoblasts express VEGF receptor (VEGFR)-1 and 2 and neuropilin (Nrp),11,12 and treatment of mice with a soluble, neutralizing VEGFR decreased angiogenesis, bone formation, and callus mineralization in femoral fractures. In other studies, blocking the function of VEGF with an antiangiogenic agent (TNP-470) or when mice lacked the expression of VEGF isoforms VEGF164 and VEGF188 impaired every step

1Stem Cell Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
2Department of Anesthesiology, West Penn Hospital, Pittsburgh, Pennsylvania.
of endochondral bone formation and led to decreased angiogenesis and bone formation.\textsuperscript{13,14} Conversely, exogenous VEGF enhanced blood vessel formation, ossification, and new bone (callus) maturation in mouse femur fractures and promoted bony bridging of a rabbit radius segmental gap defect.\textsuperscript{12} Therefore, VEGF is an essential growth factor in regulating the process of endochondral bone formation.

Several studies have applied VEGF in combination with bone morphogenetic protein 4 (BMP4) to promote endochondral bone formation. One study demonstrated that a poly- (lactic-co-glycolic acid) scaffold containing combinations of human bone marrow stromal cells and condensed plasmid DNA encoding BMP4 or VEGF elicited greater bone formation than any single factor alone or combination of the other two factors.\textsuperscript{15} Our group has previously reported the synergistic effect of VEGF and BMPs on promoting endochondral bone formation by using muscle-derived stem cells (MDSCs).\textsuperscript{16,17} In these studies, the MDSCs were retrovirally transduced to express VEGF, BMP2, or BMP4; the resulting cell populations were then combined at different ratios, based on the number of BMP-expressing cells to VEGF-expressing cells, and implanted into a gluteofemoral (GF) skeletal muscle pocket of mice. A ratio of 5:1, which corresponded to the implantation of five BMP4-expressing MDSCs for every VEGF-pocket of mice. A ratio of 5:1, which corresponded to the number of BMP-expressing cells to VEGF-expressing cell populations were then combined at different ratios, based on the number of BMP-expressing cells to VEGF-expressing cells, and implanted into a gluteofemoral (GF) skeletal muscle pocket of mice. A ratio of 5:1, which corresponded to the implantation of five BMP4-expressing MDSCs for every VEGF-pocket of mice. A ratio of 5:1, which corresponded to the number of BMP-expressing cells to VEGF-expressing cell populations were then combined at different ratios, based on the number of BMP-expressing cells to VEGF-expressing cells, and implanted into a gluteofemoral (GF) skeletal muscle pocket of mice.

To determine how the stable ratio of BMP4 to VEGF in vivo might affect VEGF’s promoting role in endochondral bone formation induced by cell-based gene therapy, we used a cell-mediated double-gene co-expressing approach that kept the ratio of BMP4 to VEGF constant over time. To do so, two easily accessible mouse cell lines were used in the present study. C212 cells (mouse myoblasts) and NIH/3T3 cells (mouse fibroblasts) were transduced with a retroBMP4 virus only or a combination of retroBMP4 and retroVEGF viruses, and their osteogenic potential was compared at different time points in vitro and postimplantation in vivo.

Materials and Methods

Cell culture

C212 cells and NIH/3T3 cells were purchased from the American Type Culture Collection (Manassas, VA). All cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin-streptomycin and incubated at 37°C in humidified air mixed with 5% carbon dioxide (CO₂).

Construction of retroviral vectors expressing lacZ, human BMP4, and VEGF

A retrovirus carrying genes for the nuclear localizing signal and β-galactosidase was produced from a stably transfected cell line known as Tel-6.\textsuperscript{18} RetroBMP4 is an MFG-based retroviral vector containing the human BMP4 gene plasmid, pCLbMP4. Retroviral vectors expressing human VEGF were constructed by cloning the VEGF165cDNA (InvivoGen, San Diego, CA) into pCLX, resulting in pCLVEGF.\textsuperscript{16} The retroviruses expressing BMP4 and VEGF were termed retroBMP4 and retroVEGF, respectively.

Cell transduction using the same concentration of retroBMP4 and retroVEGF

C212 cells were seeded at a density of 1.5×10⁵ cells per 75-cm² flask and were grown to 50% confluence. On the day of transduction, cells were washed twice with sterile Phosphate Buffered Saline (PBS) and incubated with a mixture of 10 mL of retroBMP4 viral suspension (1×10⁶–5×10⁶ colony forming units (cfu)/mL), 10 mL of DMEM supplemented with 10% FBS, and hexadimethrine bromide (8 μg/mL). Transduction was carried out at 37°C in 5% CO₂ for a total of 48 h, and the viral suspension was replaced at 16 h and 32 h. The culture medium from C212 cells transduced with retroBMP4 (C212-B) was collected after 48 h, centrifuged for 5 min at 2000 rpm at 4°C to remove cellular debris, and used to perform a BMP4 bioassay.

Cells were then transduced a second time with retroVEGF. The same protocol as described above was used for this second transduction. C212-B cells were cultured in retroVEGF viral suspension (1×10⁶–5×10⁶ cfu/mL) for a total of 48 h, with medium being changed every 16 h, as described above. The culture medium from C212-B cells transduced with retroVEGF (C212-B-V) was collected after 48 h, centrifuged for 5 min at 2000 rpm at 4°C, and used to perform a VEGF assay (Enzyme-Linked ImmunoSorbent Assay (ELISA)). C212 cells were also transduced solely with a retroVEGF to create the C212-V cells, following the same protocols detailed above. NIH/3T3 cells were transduced and analyzed using the same methods as the C212 cells. NIH/3T3 cells transduced with retroBMP4 were termed 3T3-B, and these 3T3-B cells were then transduced with retroVEGF and named 3T3-B-V. Exclusively for the C212-B-V cell group, they were transduced a third time with a retroLacZ virus according to the protocol described above, which yielded the C212-B-V-L cell group for the in vivo experiments.

Cell transduction with retroBMP4 and various concentrations of retroVEGF

RetroVEGF suspension used in the previous section was diluted 0, 5, and 50-fold, and used to transduce C212-B and 3T3-B cells according to the protocol described above. This resulted in the following cell groups: C212-B-V50 (retroVEGF diluted by a factor of 50), C212-B-V5 (retroVEGF diluted by a factor of 5), and C212-B-V0 (undiluted retroVEGF). For the 3T3 cells, the new populations were also named according to the retroVEGF dilution (3T3-B-V50, 3T3-B-V5, 3T3-B-V0).

BMP4 bioassay and quantification of VEGF production using untransduced and transduced cells

A previously described BMP4 bioassay\textsuperscript{19} was used to determine the level of bioactive BMP4 secreted by the transduced cells. ELISA kits (Human VEGF ELISA Kit, R&D Systems, Minneapolis, MN) were used to quantify the amount of VEGF being secreted by the transduced cells.
Cell proliferation assay

C2C12, C2C12-V, C2C12-B, and C2C12-B-V were assayed for their cell proliferation rate in cell culture medium (DMEM with 1% FBS). A 200-μL cell suspension of C2C12, C2C12-V, C2C12-B, and C2C12-B-V cells was plated in triplicate on the 96-well plates (6.25×10^3 cells/well). Cells were cultured in the 96-well plates for 2 days, after which 20 μL of CellTiter 96 AQUEOUS One Reagent (Promega, Madison, WI) was added to each well. The plate was subsequently incubated in 5% CO₂ at 37°C for 2.5h, and the absorbance was read at 490 nm using a 96-well plate reader. NIH/3T3 cell groups were investigated in the same manner.

Pellet culture

Mineralization assay. The four transduced cell groups (C2C12-B, C2C12-B-V, 3T3-B, 3T3-B-V) were cultured as pellets to evaluate calcification in vitro. Briefly, 2.5×10^5 cells were centrifuged at 500 g in 15-mL polypropylene conical tubes, and the resulting pellets were cultured for up to 4 weeks in osteogenic medium (DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, 10^{-5} M dexamethasone, 50 μg/mL ascorbic-acid-2-phosphate, and 10^{-2} M β-glycerophosphate), which was changed every 2 to 3 days. Samples were harvested on days 7, 14, 21, and 28 and embedded in paraffin block. Pellet sections were stained with von Kossa/eosin staining.

Chondrogenesis assay. 3T3-B and 3T3-B-V cells were made into pellets as described above and cultured in chondrogenic medium (Lonza Group Ltd, Basel, Switzerland). Samples were harvested on days 21 and 28 and embedded in a paraffin block, and the pellet sections were stained with Alcian blue/nuclear fast red.

Terminal deoxynucleotidyl transferase 2’-deoxyuridine 5’-triphosphate nick end labeling assay. The deparaffinized chondrogenic pellet sections of 3T3-B and 3T3-B-V were digested with proteinase K following the protocol provided by the manufacturer (ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit, Chemicon, Temecula, CA). The terminal deoxynucleotidyl transferase 2’-deoxyuridine 5’-triphosphate nick end labeling (TUNEL) stain was visualized using a substrate system that stained purple (VIP Substrate Kit, Vector Laboratories, Burlingame, CA). After staining, the sections were examined under the microscope, and positive cells found in the center area of the pellets were quantified.

Western blot analysis for the expression of Nrp-1 and hypoxia-inducible factor 1 subunit alpha in 3T3 cells

3T3, 3T3-B, and 3T3-B-V cell lysates in sample buffer (2-mercaptoethanol and Laemmli sample buffer, Bio-Rad Laboratories, Hercules, CA) were collected, incubated in boiling water for 5 min, and centrifuged, and the supernatant was stored at 4°C. Samples were resolved on 10% sodium dodecyl sulfate–polyacrylamide gels and then transferred to pure nitrocellulose membranes (Bio-Rad Laboratories). The membranes were treated as detailed in the manufacturer’s protocol (Vectastain ABC-AmP, Vector Laboratories). Anti-nrp-1 (PC343T, 1:100, Calbiochem, San Diego, CA) and hypoxia-inducible factor 1 subunit alpha (HIF-1α) antibody (38-9800, 1:100, Zymed, South San Francisco, CA) were used for this experiment.

Viability assay of 3T3, 3T3-B, and 3T3-B-V cells

Three groups of 3T3 cells were plated in triplicate on the 96-well plates (1.25×10^4 cells/well). Cells were cultured in DMEM supplemented with 1% FBS and 100 μM or 400 μM hydrogen peroxide (H₂O₂) in the 96-well plates for 2 days. After 2 days, 20 μL of CellTiter 96 AQUEOUS One Reagent (Promega, Madison, WI) was added to each well; the plate was subsequently incubated for 2.5h, and the absorbance was read at 490 nm using a 96-well plate reader.

Preparation of gelatin sponge implants

A 100-μL cell suspension containing 2×10^5 cells (for each group of C2C12 and NIH/3T3 cells) was seeded on the surface of a 6-× 6-mm piece of sterile gelatin sponge (Gelfoam; Pharmacia & Upjohn Co, Kalamazoo, MI). After the Gelfoam absorbed the cell suspension, 3 mL of DMEM supplemented with 10% FBS was added to each well, and the implants were incubated overnight. The following day, the seeded Gelfoam scaffolds were implanted into the skeletal muscle pocket of the gluteofemoral muscles of severe combined immunodeficient mice. The mice were sacrificed at 7, 10, 14, 20, 27, and 35 days after cell implantation. All animal experiments were conducted with the approval of the Animal Research and Care Committee of the Children’s Hospital of Pittsburgh.

Radiographic and histological analyses

Ectopic bone formation was monitored using X-ray examination of the mice at day 28 postimplantation (Model MX-20, Faxitron X-ray Corporation, Lincolnshire, IL). To visualize mineralized matrix deposition and bone volume analysis in vitro and in vivo, a micro computed tomography (microCT) imaging system (vivaCT40; Scanco Medical, Baselsdorf, Switzerland) was used to scan all of the osteogenic pellets and in vivo samples. Tissue samples were obtained at sacrifice, treated with CRYO-GEI Embedding Medium (Cancer Diagnostics, Inc, Birmingham, MI), rapidly frozen in liquid nitrogen precooled 2-methylbutane (Sigma, St. Louis, MO), and stored at −80°C. Frozen sections were stained as detailed below.

Alcian blue/eosin staining

A 1% Alcian blue solution was made with 3% acetic acid. Frozen sections were fixed in 10% neutral buffered formalin for 10 min and rinsed in distilled water. Slides were placed in 3% acetic acid for 3 min and then transferred into the Alcian blue solution for 30 min, after which they were rinsed in running tap water for 1 min and counterstained with eosin.

Von Kossa/eosin staining

Frozen sections were fixed in 10% neutral buffered formalin for 10 min, followed by 3 rinses in distilled water. The slides were then stained in 2% silver nitrate solution in the dark for 15 min, rinsed three times in distilled water, and exposed to light for 15 to 30 min until appropriate stain development was achieved, after which the sections were counterstained with eosin.
Human BMP4 and VEGF immunostaining and hematoxylin staining

The sections were processed for human BMP4 immunostaining as suggested in the manufacturer’s protocol (Vectorstain Elite ABC kit, Dab Substrate Kit for Peroxidase; Vector Laboratories). Human BMP4 antibody (1:100 dilution, AF757; R&D Systems) and human VEGF antibody (1:100 dilution, AB-293NA; R&D Systems) were used for the immunostaining. These sections were counterstained with hematoxylin.

Quantitative measurement of newly formed cartilage, bone, and the density of human BMP4 and VEGF staining

Full views of histological sections were obtained using microscopy, and various measurements were obtained with Northern Eclipse imaging software (Empix Imaging Inc., Mississauga, Canada). A measurement of the cartilage formation was obtained by analyzing the blue area, which indicated a positive reaction with Alcian blue. A measurement of bone formation was obtained by analyzing the black area, which indicated a positive reaction to von Kossa staining. A measurement of the density of the human BMP4 and VEGF staining was obtained using Northern Eclipse software to analyze the level of brown color, which indicated the positive expression of human BMP4 and VEGF (i.e., a positive result after treatment with the Dab Substrate Kit for Peroxidase).

Immunostaining for lacZ and CD31 in tissue sections of C2C12-B-V-L cells

Tissue sections were fixed in acetone:methanol (1:1) at room temperature for 5 min and then blocked with 7.5% donkey serum and 7.5% goat serum for 30 min. CD31 antibody (1:200 dilution, BD 553370) and lacZ antibody (1:200 dilution, Abcam) were added to the tissue sections for 3 h at room temperature. Sections were washed in PBS three times for 5 min. Secondary antibodies, goat anti-rat 555 (1:300 dilution) and donkey anti-rat 488 (1:300 dilution), were added to sections for 1 h at room temperature. 4’6-diamidino-2-phenylindole (1:1000 dilution) was added to sections for 5 min. Sections were washed in PBS three times and examined under a fluorescence microscope.

FIG. 1. Growth factors secretion and proliferation rate of genetically engineered cells. (A) Amount of recombinant human bone morphogenetic protein 4 (rhBMP4) secreted by C2C12-B and 3T3-B into the culture medium. (B) Amount of recombinant human vascular endothelial growth factor (rhVEGF) secreted by C2C12-B-V and 3T3-B-V into the culture medium. (C, D) Proliferation of the different populations of (C) C2C12 and (D) 3T3 cells before and after transduction with retroVEGF, retroBMP4, or both. **P < 0.01 indicates a significant difference between (C) C2C12-B and all other C2C12 groups, and between (D) the 3T3 groups.
Statistical analysis

Data are reported as means ± standard deviations and analyzed using two-way analysis of variance with Tukey’s post hoc test.

Results

Expression of human BMP4 and VEGF from transduced C2C12 and NIH/3T3 cells

The two types of cells used in this study were both able to synthesize, process, and secrete active recombinant human (rh) BMP4 after transduction with retroBMP4. The amount of secreted rhBMP4 reached 105 ± 10 ng/million cells per 24 h in C2C12 cells and 98 ± 5 ng/million cells per 24 h in NIH/3T3 cells (Fig. 1A). The two types of BMP4-expressing cells transduced with retroVEGF secreted rhVEGF at a level of 152 ± 20 ng/million cells per 24 h in C2C12 cells and 128 ± 12 ng/million cells per 24 h in NIH/3T3 cells (Fig. 1B). In terms of β-galactosidase gene (LacZ) transduction efficiency, 75% of the C2C12-B-V cells were LacZ positive.

Differential effects of BMP4 and VEGF on the proliferation rate of C2C12 and NIH/3T3 cells

C2C12-V showed a proliferation potential similar to that of the non-transduced C2C12 cells (Fig. 1C). When the C2C12 cells were transduced with retroBMP4 (C2C12-B), their

FIG. 2. Mineralization potential and chondrogenic differentiation of C2C12 and NIH/3T3 in vitro. With von Kossa/eosin staining, the calcified tissue is stained black and surrounding tissue is stained red. (A) C2C12-B-V cell pellets displayed less mineralization than the C2C12-B cells at different time points when cultured in osteogenic medium (scale bar represents 250 µm). (B) Micro computed tomography analysis showed that C2C12-B pellets had more mineralized tissue than C2C12-B-V pellets at days 7 and 14 (*p < 0.05). (C) The 3T3-B-V cell pellets also showed less mineralization than 3T3-B cells (scale bar represents 250 µm). (D) With Alcian blue staining, cells in the 3T3-B-V group showed more cells with normal morphology than the 3T3-B group (scale bar represents 50 µm). (E) Western blot analysis revealed a differential expression of neuropilin-1 (Nrp1) and hypoxia-inducible factor 1 subunit alpha (HIF-1α) in three 3T3 cell groups. (F) Terminal deoxynucleotidyl transferase 2'-deoxyuridine 5'-triphosphate nick end labeling staining of chondrogenic pellets showed less apoptosis in the 3T3-B-V pellets than the 3T3-B pellets at day 28 (*p < 0.05), whereas no difference was observed at day 21. (G) Oxidative stress analysis showed that 3T3-B-V cells displayed better survival than 3T3-B cells when cultured with 100 µM and 400 µM of hydrogen peroxide (*p < 0.05).
proliferation potential was significantly greater than that of the C2C12 and C2C12-V cells (p < 0.01) (Fig. 1C). However, C2C12-B-V cells displayed significantly poorer proliferation potential than the C2C12-B cells (p < 0.01) (Fig. 1C).

3T3 cells and 3T3-V cells displayed similar proliferation rates (Fig. 1D). 3T3-B demonstrated a significantly greater proliferation rate than the 3T3 and 3T3-V cell groups (p < 0.01) (Fig. 1D). Transducing these cells to express BMP4 and VEGF (3T3-B-V) led to a significantly greater proliferation rate than that of all other 3T3 cell groups (p < 0.01) (Fig. 1D).

Pellet culture

In the in vitro mineralization assay, C2C12-B and 3T3-B cell pellets directly calcified without going through a chondrogenic phase when cultured in the osteogenic medium. The C2C12-B-V and 3T3-B-V cell groups showed less calcification than the corresponding C2C12-B and 3T3-B cell groups at different time points (days 7, 14, 21, and 28) (Fig. 2A, C). MicroCT analysis showed that C2C12-B-V pellets displayed significantly less calcified tissue than C2C12-B cell pellets at days 7 and 14 of culture (p < 0.05) (Fig. 2B). Results of Alcian blue staining showed that the 3T3-B-V cells exhibited more cells with normal morphology in the center of the pellet than was seen with the 3T3-B cells (Fig. 2D). Western blot analysis showed that the 3T3-B and 3T3-B-V cells expressed similar levels of Nrp-1 and HIF-1α and that both expressed higher levels than the nontransduced 3T3 cells (Fig. 2E). TUNEL staining revealed that pellets made with 3T3-B-V cells had significantly less apoptotic cells than 3T3-B pellets at day 28 of culture (p < 0.05) (Fig. 2F).

Survival analysis of different groups of 3T3 cells

3T3-B-V cells showed significantly higher resistance to oxidative stress than 3T3-B cells when cultured in H2O2-supplemented DMEM at different concentrations (100 μM and 400 μM) (p < 0.05) (Fig. 2G).

Differential endochondral bone formation displayed by two types of cells transduced with retroBMP4 or a combination of retroBMP4 and retroVEGF

C2C12-B cells displayed normal cartilage formation. In the C2C12-B-V group, no cartilage was found at any of the time points tested, yet irregular empty channels were observed (Fig. 3A, C). Although the cartilaginous phase of endochondral bone formation seen with 3T3-B and 3T3-B-V cells was...
similar at early time points, the 3T3-B-V cells displayed a significantly greater cartilage area at 27 and 35 days post implantation (Fig. 3B, D).

In the case of bone formation, the C2C12-B cell group showed normal bone production (Fig. 4A) (Supplemental Fig. 1, available online at www.liebertonline.com = ten). Implantation of C2C12-B-V cells demonstrated bone tissue formation. C2C12-B-V cells did not generate any bone tissue but merely produced a lattice of irregular channels within the soft tissues (scale bars represent 100 μm). The bone area (in pixels) of C2C12-B was significantly larger than that of C2C12-B-V at different time points (**p < 0.01 at days 10–35). (B, D) 3T3-B cells exhibited a normal pattern of bone formation, whereas 3T3-B-V cells showed poorer bone formation with time (scale bars represent 100 μm). The bone area (in pixels) seen with the 3T3-B cell group was significantly larger than that of the 3T3-B-V cell group (**p < 0.01 at days 20–35). (E) X-ray analysis at day 28 after implantation showed that the C2C12-B cell group displayed an area of high density in the gluteofemoral muscle pocket of severe combined immunodeficient mice, whereas the C2C12-B-V cells showed no radio-opaque area in the muscle pocket. (F) X-ray analysis at day 28 after implantation showed that 3T3-B cells produced an area of high density in the muscle pocket, whereas 3T3-B-V cells exhibited no radio-opaque area in the muscle pocket.
FIG. 5. Expression of human bone morphogenetic protein (BMP)4 and vascular endothelial growth factor (VEGF) in vivo. (A, B) Staining of the tissue obtained from the C2C12-B-V group at different time points postimplantation showed that human VEGF and BMP4 expression levels increased with time in vivo. (C, D) 3T3-B-V cells also showed greater human VEGF and BMP4 expression level with time. (E) Gross appearance of the in vivo tissue sample from the C2C12-B-V group that was stained with hematoxylin and eosin showed a hemangioma-like structure that stained positive for human BMP4 and VEGF (positive = brown color) (scale bar represents 3000 μm). (F) The tissue section stained for CD31 and LacZ immunofluorescence (scale bar represents 100 μm) revealed that most cells in the tissue section are CD31 positive (green) and with only a cell positive for both LacZ (red nuclei) and CD31 (green) (arrowhead) (scale bar represents 25 μm) under a higher magnification.
Quantitative measurement of human BMP4 and VEGF immunostaining

Human BMP4 and VEGF immunostaining results of in vivo samples (implanted C2C12-B-V and 3T3-B-V cells) at different time points revealed that BMP4 and VEGF expression levels increased with time (Fig. 5A-D).

Results of histological and immunohistochemical staining

Hematoxylin and eosin staining revealed that C2C12-B-V cells induce a hemangioma-like structure. When these tissues were immunostained with human BMP4 or human VEGF, both proteins were expressed in the tissue sections (Fig. 5E). Although most of the cells in the hemangioma-like structures stained positive with CD31, double staining with LacZ and CD31 indicated that most of the CD31-positive cells were negative for lacZ staining (Fig. 5F).

Co-expression of BMP4 and VEGF at different ratios influence the mineralization potential

C2C12-B and 3T3-B cells secreted different amounts of VEGF after transduction with various concentrations of retroVEGF (V50, V5, and V0; Fig 6A, B). The level of secreted VEGF of C2C12-B-V50, C2C12-B-V5, and C2C12-B-V0 reached 16 ± 5 ng/million cells per 24 h, 60 ± 8 ng/million cells per 24 h, and 440 ± 24 ng/million cells per 24 h, respectively. The secreted VEGF level of 3T3-B-V50, 3T3-B-V5, and 3T3-B-V0 reached 4 ± 1 ng/million cells per 24 h, 30 ± 5 ng/million cells per 24 h, and 150 ± 12 ng/million cells per 24 h, respectively. When these various populations of C2C12 and 3T3 cells were implanted in vivo, and the mineralized tissue was quantified using microCT, less mineralized potential was observed with greater concentration of secreted VEGF. The cells transduced with nondiluted retroVEGF (C2C12-B-V0 and 3T3-B-V0) displayed the lowest amount of mineralized tissue volume, whereas cells transduced with a retroVEGF diluted by a factor of 5 and 50 showed significantly greater mineralized tissue volume than the V0 group (Fig. 6C-F).

Discussion

Previous studies have shown that VEGF has a promoting effect on endochondral bone formation induced by BMP4,16,17 but these studies have relied on the separate delivery of BMP4 and VEGF by transducing cells to express BMP4 or VEGF and then implanting them at certain ratios. Because of this limitation, the possibility cannot be excluded that the BMP4-transduced cells may proliferate at a different rate than the VEGF-transduced cells and consequently influence the initial established ratio of BMP4 to VEGF several days post-implantation. The current study confirmed these differences in proliferation rate by comparing the proliferation rates of untransduced cells with those of cells transduced to express VEGF, BMP4, or both. In the case of C2C12 and NIH/3T3 cells, cells transduced with a retroBMP4 had a greater proliferation rate than the cells expressing VEGF alone. For this reason, it remains unclear how a ratio of BMP4 to VEGF that remains constant in vivo might affect VEGF’s promoting role in endochondral bone formation. In this study, we aimed to keep the BMP4:VEGF ratio constant by transducing C2C12 and NIH/3T3 to simultaneously express BMP4 and VEGF. Hence, regardless of the proliferation rate differences, the ratio of BMP4 to VEGF would remain constant over time.

C2C12 cells transduced to express BMP4 have previously been shown to form bone when implanted into the intramuscular pocket of mice.20 In the present study, when C2C12-B-V cells were analyzed for their ability to form mineralized tissue in vivo, it was determined that the co-expression of VEGF inhibited the calcification seen with BMP4-expressing C2C12 cells cultured as pellets in osteogenic medium. This lack of mineralization in vitro might explain the subsequent lack of bone formation in vivo with the C2C12-B-V cell group, although it is not thought to be the sole explanation, because cell pellets made with C2C12-B-V cells still displayed a certain amount of calcification at days 21 and 28 when cultured in osteogenic medium in vitro. Another possibility is that the implanted C2C12-B-V cells may have differentiated into endothelial cells instead of osteoblasts under the synergistic effect of BMP4 and VEGF, although when we followed the fate of the donor cells using LacZ staining, we observed that few donor cells co-expressed the endothelial cell marker CD31, suggesting that the C2C12-B-V cells did not readily differentiate into endothelial cells. The findings observed with C2C12 cells transduced to express BMP4 and VEGF are in accordance with the results from another study that demonstrated that BMP2 could induce vascularization, enhance angiogenesis, and result in vascularized tumor formation.21 We therefore postulate that implanted C2C12-B-V cells continuously overexpressed VEGF and recruited host cells in vivo that consequently participated in the in vivo formation of the hemangioma-like structures observed.

Unlike the findings obtained with C2C12-B-V cells, implantation of 3T3-B-V cells led to the formation of tissues filled with a prolonged and more-persistent cartilaginous phase. These findings are in accordance with our previous study, which reported that NIH/3T3 cells have a distinctly greater potential for producing cartilage, both in vitro and in vivo, when treated with BMP4.20 The 3T3-B-V cell group produced more cartilage and less bony tissue than the 3T3-B cell group at the different time points (days 27 and 35) after in vivo implantation. The mechanism was believed to be different from that of C2C12-B-V cells. The 3T3-B-V cells displayed a greater proliferation potential than the 3T3-B cells, which demonstrated the promoting effect of BMP4 and VEGF on the proliferation of NIH/3T3 cells. In addition, 3T3-B-V cell pellets cultured in chondrogenic medium showed less cell apoptosis than the pellets made with 3T3-B cells. Western blot analysis showed that the co-transduced NIH/3T3 with retroBMP4 and retroVEGF upregulated HIF-1α and the VEGFR Nrp-1. It has been reported that HIF-1α regulates the transcription of a broad range of genes that are involved in a variety of processes such as glucose metabolism, angiogenesis, and cell survival.22–25 Nrp-1 is a co-receptor membrane-bound to a tyrosine kinase receptor for VEGF that plays a role in angiogenesis, axon guidance, cell survival, migration, and tumor invasion.11 Our results also indicated that 3T3-B-V cells had a better cell survival rate than 3T3-B and 3T3 cells when they were exposed to oxidative stress. Hence, the greater proliferation and survival potential displayed by 3T3-B-V cells than by 3T3-B cells might explain, at least in part, the observation that cartilage formation was found in the 3T3-B-V cell group in vivo. With regard to the poorer bone production seen in this group than in the 3T3-B group, the
explanation is thought to be that a constant high level of VEGF expression could inhibit the calcification of 3T3-B-V cells in vivo, which was supported by the observation that cell pellets made with 3T3-B-V cells have less calcification than those made with 3T3-B cells at different time points (days 7, 14, 21, and 28) when cultured in osteogenic medium in vitro.

Transducing C2C12-B and 3T3-B cells with different concentrations of retroVEGF further confirmed that co-expression of VEGF and BMP4 lead to impaired mineralized tissue formation, especially with high doses of VEGF. Although diluting the retroVEGF by a factor of 5 still impaired bone formation, the dilution by a factor of 50 eliminates the detrimental effect and consequently induces mineralized tissue formation similar to that of the BMP4-only transduced cells. Therefore, these results suggest that co-expression of BMP4 and VEGF in our experimental setting impaired ectopic endochondral bone formation, especially when the ratio of VEGF to BMP4 was high. However, if the ratio of VEGF to BMP4 is kept low and constant, then the detrimental effect on the ectopic bone formation is lost.

In summary, the present study demonstrated that co-expression of VEGF and BMP4 influenced ectopic endochondral bone formation and provided additional knowledge as to the importance of the BMP:VEGF ratio for this process. Although our results indicate that a high ratio of VEGF to BMP4 led to a detrimental effect on bone formation, we have also observed that, if the ratio of VEGF to BMP4 is kept low and constant for a prolonged period of time, detrimental effect of VEGF on bone formation is lost. Therefore, when developing cell-based gene therapies for tissue engineering, it will be important to thoroughly investigate not only the benefits of growth factors, but also their interaction, their respective doses and timing of action, and finally their effect on given cell types.

Acknowledgments

This work was supported in part by a National Institutes of Health grant (1 R01 DE13420-06) to J. Huard. This work was also supported by the William F. and Jean W. Donaldson...
Chair at Children's Hospital of Pittsburgh and by the Henry J. Mankin Endowed Chair in Orthopaedic Surgery at the University of Pittsburgh. This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number C06 RR-14489 from the National Center for Research Resources, National Institutes of Health.

Disclosure Statement

No competing financial interests exist.

References


Address correspondence to:
Johnny Huard, Ph.D.
Stem Cell Research Center
Children's Hospital of Pittsburgh
4100 Rangos Research Center
3460 Fifth Avenue
Pittsburgh, PA 15213

E-mail: jhuard@pitt.edu

Received: April 11, 2008
Accepted: December 11, 2008
Online Publication Date: February 9, 2009
This article has been cited by:

1. Dr. Yuan Deng, Prof. Huifang Zhou, Dr. Chenxi Yan, Dr. Yefei Wang, Dr. Ciwen Xiao, Prof. Ping Gu, Prof. Xianqun Fan. In vitro osteogenic induction of BMSCs with encapsulated gene modified BMSCs and in vivo implantation for orbital bone repair. *Tissue Engineering Part A* 018:19–20, 2095-2105. [Abstract] [Full Text PDF] [Full Text PDF with Links]


3. Laura Kyllönen, Suvi Haimi, Janne Säkkinen, Hannu Kuokkanen, Bettina Mannerström, George K. B. Sándor, Susanna Miettinen. 2013. Exogenously added BMP-6, BMP-7 and VEGF may not enhance the osteogenic differentiation of human adipose stem cells. *Growth Factors* 1-13. [CrossRef]


